Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

5-methoxy-N,N- dimethyltryptamine - Biomind Labs

Next Previous
Drug Profile

5-methoxy-N,N- dimethyltryptamine - Biomind Labs

Alternative Names: 5-MeO-DMT-Biomind Labs; BMND-05; BMND-08

Latest Information Update: 21 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biomind Labs
  • Class Analgesics; Anti-inflammatories; Antidementias; Antidepressants; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Ethers; Mood stabilisers; Small molecules; Tryptamines
  • Mechanism of Action Serotonin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease
  • Preclinical Pain

Most Recent Events

  • 15 Mar 2025 Biomind Labs completes a phase I/II trial for Alzheimer’s Disease (Mid-stage disease) in Argentina (Sublingual) (NCT06812221)
  • 01 Mar 2025 Biomind Labs completes a phase I/II trial for Alzheimer's disease in Argetina (Sublingual) (NCT06816667)
  • 15 Dec 2024 Biomind Labs initiates enrolment in a phase I/II trial for Alzheimer’s Disease (Mid-stage disease) in Argentina (Sublingual) (NCT06812221)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top